

M J Gooderham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1881143/publications.pdf>

Version: 2024-02-01

104
papers

5,875
citations

126858

33
h-index

79644

73
g-index

104
all docs

104
docs citations

104
times ranked

4530
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2287-2303. | 6.3 | 884 |
| 2 | Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2017, 376, 1551-1560. | 13.9 | 413 |
| 3 | Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). <i>British Journal of Dermatology</i> , 2015, 173, 1387-1399. | 1.4 | 384 |
| 4 | Topical tofacitinib for atopic dermatitis: a phase III randomized trial. <i>British Journal of Dermatology</i> , 2016, 175, 902-911. | 1.4 | 356 |
| 5 | Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. <i>New England Journal of Medicine</i> , 2018, 379, 1313-1321. | 13.9 | 301 |
| 6 | Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 863. | 2.0 | 247 |
| 7 | Dupilumab: A review of its use in the treatment of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, S28-S36. | 0.6 | 218 |
| 8 | Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1282-1293. | 0.6 | 214 |
| 9 | Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 576-586. | 6.3 | 198 |
| 10 | Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2019, 155, 1371. | 2.0 | 174 |
| 11 | Bimekizumab versus Secukinumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 142-152. | 13.9 | 173 |
| 12 | The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 507-517. | 1.3 | 156 |
| 13 | Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 134-142. | 0.6 | 138 |
| 14 | An update on generalized pustular psoriasis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 907-919. | 1.3 | 122 |
| 15 | Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 649. | 2.0 | 120 |
| 16 | A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. <i>British Journal of Dermatology</i> , 2020, 182, 1348-1358. | 1.4 | 117 |
| 17 | Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 855-862. | 0.6 | 104 |
| 18 | Shifting the focus – the primary role of IL-23 in psoriasis and other inflammatory disorders. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1111-1119. | 1.3 | 80 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 70-80. | 0.6 | 78 |
| 20 | The psychosocial impact of hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, S19-S22. | 0.6 | 73 |
| 21 | Trial of Roflumilast Cream for Chronic Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2020, 383, 229-239. | 13.9 | 71 |
| 22 | A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blind trial*. <i>British Journal of Dermatology</i> , 2021, 184, 1047-1058. | 1.4 | 58 |
| 23 | Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018, 179, 615-622. | 1.4 | 57 |
| 24 | Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020, 10, 133-150. | 1.4 | 51 |
| 25 | Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. <i>BioDrugs</i> , 2015, 29, 327-339. | 2.2 | 50 |
| 26 | Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). <i>British Journal of Dermatology</i> , 2018, 178, 1315-1323. | 1.4 | 44 |
| 27 | The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 298-306. | 0.6 | 43 |
| 28 | Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. <i>Drugs in Context</i> , 2020, 9, 1-9. | 1.0 | 43 |
| 29 | Review of Systemic Treatment Options for Adult Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 31-39. | 0.6 | 42 |
| 30 | Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis. <i>Core Evidence</i> , 2018, Volume 13, 13-20. | 4.7 | 41 |
| 31 | Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 431-447. | 1.4 | 40 |
| 32 | Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 513-524. | 0.6 | 39 |
| 33 | A Review of Psoriasis, Therapies, and Suicide. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 293-303. | 0.6 | 37 |
| 34 | Long-term topical management of psoriasis: the road ahead. <i>Journal of Dermatological Treatment</i> , 2022, 33, 111-120. | 1.1 | 37 |
| 35 | Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of age. <i>British Journal of Dermatology</i> , 2014, 171, 1470-1477. | 1.4 | 32 |
| 36 | Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. <i>Dermatology and Therapy</i> , 2022, 12, 495-510. | 1.4 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab. Journal of Cutaneous Medicine and Surgery, 2020, 24, 588-595. | 0.6 | 29 |
| 38 | 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. Journal of Cutaneous Medicine and Surgery, 2016, 20, 375-431. | 0.6 | 28 |
| 39 | Psoriasis Prevalence and Severity by Expert Elicitation. Dermatology and Therapy, 2021, 11, 1053-1064. | 1.4 | 28 |
| 40 | Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1324-1332. | 1.3 | 23 |
| 41 | TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors. International Journal of Dermatology, 2022, 61, 139-147. | 0.5 | 23 |
| 42 | Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. Journal of Rheumatology, 2019, 46, 751-754. | 1.0 | 22 |
| 43 | Abrocitinib for the treatment of atopic dermatitis. Expert Review of Clinical Immunology, 2020, 16, 955-962. | 1.3 | 21 |
| 44 | Phosphodiesterase-4 Inhibition in Psoriasis. Psoriasis: Targets and Therapy, 2021, Volume 11, 21-29. | 1.2 | 21 |
| 45 | Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology, 2022, 86, 77-85. | 0.6 | 21 |
| 46 | Diagnosis of Generalized Pustular Psoriasis. American Journal of Clinical Dermatology, 2022, 23, 31-38. | 3.3 | 21 |
| 47 | Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. British Journal of Dermatology, 2020, 182, 1359-1368. | 1.4 | 20 |
| 48 | A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. Journal of Cutaneous Medicine and Surgery, 2018, 22, 78-83. | 0.6 | 17 |
| 49 | Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2018, 22, 21S-29S. | 0.6 | 17 |
| 50 | Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. Journal of Cutaneous Medicine and Surgery, 2020, 24, 3S-14S. | 0.6 | 16 |
| 51 | Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis. Annals of Allergy, Asthma and Immunology, 2021, 126, 576-583.e4. | 0.5 | 16 |
| 52 | The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature. Journal of Cutaneous Medicine and Surgery, 2019, 23, 289-297. | 0.6 | 15 |
| 53 | Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. International Journal of Dermatology, 2022, 61, 746-754. | 0.5 | 15 |
| 54 | Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2431-2439. | 1.3 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study. <i>Journal of Drugs in Dermatology</i> , 2020, 19, 734-740. | 0.4 | 13 |
| 56 | Management of scalp psoriasis: current perspectives. <i>Psoriasis: Targets and Therapy</i> , 2016, 6, 33. | 1.2 | 12 |
| 57 | The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 428-435. | 0.6 | 12 |
| 58 | Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of interleukin 23. <i>JAAD Case Reports</i> , 2021, 7, 60-61. | 0.4 | 12 |
| 59 | International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561. | 2.0 | 12 |
| 60 | Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. <i>Journal of Dermatology</i> , 2022, 49, 95-105. | 0.6 | 11 |
| 61 | Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a <i>post hoc</i> integrated analysis of patients with moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 855-865. | 1.3 | 11 |
| 62 | Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 30S-35S. | 0.6 | 9 |
| 63 | Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 727-740. | 1.4 | 9 |
| 64 | Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 5S-10S. | 0.6 | 8 |
| 65 | Uncommon Adverse Effects of Deoxycholic Acid Injection for Submental Fullness: Beyond the Clinical Trials. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 619-624. | 0.6 | 7 |
| 66 | Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review. <i>Dermatologic Therapy</i> , 2021, 34, e15104. | 0.8 | 7 |
| 67 | Improvement of granulomatous skin conditions with tofacitinib in three patients: A case report. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X21110394. | 0.2 | 7 |
| 68 | Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, . | 1.3 | 7 |
| 69 | Brodalumab: A Review of Safety. <i>Skin Therapy Letter</i> , 2018, 23, 1-3. | 0.3 | 7 |
| 70 | Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: <i>post hoc</i> analysis of 5-year data from <i>reSURFACE</i> 1 and <i>reSURFACE</i> 2. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1774-1783. | 1.3 | 7 |
| 71 | Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 797-806. | 1.3 | 6 |
| 72 | Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A <i>post hoc</i> analysis of PSO-LONG. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 60-67. | 1.3 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 3S-5S. | 0.6 | 5 |
| 74 | Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e350-e352. | 1.3 | 5 |
| 75 | Real-world experience of dupilumab in the treatment of moderate-to-severe atopic dermatitis. <i>International Journal of Dermatology</i> , 2020, 59, e361-e363. | 0.5 | 5 |
| 76 | Real-world experience with risankizumab in patients with plaque psoriasis: a retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e685-e688. | 1.3 | 5 |
| 77 | Apremilast in the treatment of psoriasis and psoriatic arthritis. <i>Skin Therapy Letter</i> , 2015, 20, 1-6. | 0.3 | 5 |
| 78 | Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report. <i>SAGE Open Medical Case Reports</i> , 2019, 7, 2050313X1982962. | 0.2 | 4 |
| 79 | Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 911-917. | 1.9 | 4 |
| 80 | Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. <i>Journal of Dermatological Treatment</i> , 2021, 32, 484-491. | 1.1 | 4 |
| 81 | A case report of recalcitrant aphthous ulcers in two patients treated with interleukin-17 inhibitors. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110349. | 0.2 | 4 |
| 82 | TYK2 inhibition: changing the treatment landscape for psoriasis?. <i>Expert Review of Clinical Immunology</i> , 2021, , 1-3. | 1.3 | 4 |
| 83 | High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1308-1317. | 1.3 | 4 |
| 84 | Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 282-288. | 0.6 | 3 |
| 85 | Topical PDE-4 Inhibitors are Emerging for Psoriasis Treatment. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 109-110. | 0.6 | 3 |
| 86 | Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland. <i>Journal of Dermatological Treatment</i> , 2021, , 1-19. | 1.1 | 3 |
| 87 | Lymantria dispar dispar (Gypsy) Moth Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 555-556. | 0.6 | 3 |
| 88 | Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world setting. <i>British Journal of Dermatology</i> , 2022, 186, 726-728. | 1.4 | 3 |
| 89 | Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2692-2694. | 1.1 | 3 |
| 90 | An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12. <i>British Journal of Dermatology</i> , 2020, 183, 52-59. | 1.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Treatment of Palmoplantar Pustulosis with the Combination of Ustekinumab and Apremilast: A Case Report. Archives of Case Reports in Clinical Medicine, 2016, 02, . | 0.0 | 2 |
| 92 | Return of <i>Lymantria dispar dispar</i> (gypsy moth): A case report. SAGE Open Medical Case Reports, 2021, 9, 2050313X2110579. | 0.2 | 2 |
| 93 | Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology. Dermatology and Therapy, 2022, 12, 253-265. | 1.4 | 2 |
| 94 | Predictors of Topical Use in Psoriasis Patients in the REFINE Study. Journal of Cutaneous Medicine and Surgery, 2016, 20, 106-112. | 0.6 | 1 |
| 95 | The effectiveness of intralesional <i>Candida</i> antigen immunotherapy as a treatment for anogenital warts: a retrospective chart review. Journal of the European Academy of Dermatology and Venereology, 2022, 36, . | 1.3 | 1 |
| 96 | Reverse koebnerization of primary cutaneous follicle center lymphoma following skin biopsy. JAAD Case Reports, 2021, 16, 149-151. | 0.4 | 1 |
| 97 | Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab. Journal of Cutaneous Medicine and Surgery, 2022, , 120347542210885. | 0.6 | 1 |
| 98 | Healthcare Providers Face Numerous Challenges in Treating Patients with Psoriasis: Results from a Mixed-Methods Study. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 35-43. | 0.3 | 1 |
| 99 | Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and Therapy, 2022, 12, 1073-1089. | 1.4 | 1 |
| 100 | Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot. Blockchain in Healthcare Today, 0, , . | 3.4 | 0 |
| 101 | Visual Dermatology: Achenbach Syndrome (Paroxysmal Finger Hematoma). Journal of Cutaneous Medicine and Surgery, 2022, , 120347542110733. | 0.6 | 0 |
| 102 | Alitretinoin: An Update of Real-World Evidence in The Management of Chronic Hand Dermatitis. Skin Therapy Letter, 2018, 23, 1-4. | 0.3 | 0 |
| 103 | Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 117-121. | 0.3 | 0 |
| 104 | Practice Patterns Around the Management of Atopic Dermatitis in 2018 and 2020. Journal of Cutaneous Medicine and Surgery, 2022, , 120347542210996. | 0.6 | 0 |